Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.The safety pro ...

Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...

At last week's JPMorgan conference, Biogen chief executive Chris Viehbacher said the company is open to additional bolt-on acquisitions, like its 2023 purchase of Reata Pharma and its rare disease ...

Aduhelm’s demise, and an expected slow take-up of Leqembi, came as the company’s longstanding ... of a planned $7.3 billion takeover of Reata Pharma, aimed at bolstering its product portfolio ...

Novartis Pharmaceuticals is removing hundreds of New Jersey employees from its company. The global drugmaker will lay off 427 ...

ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 ...

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing ...

Bankrupt drugmaker Purdue Pharma filed a new bankruptcy plan on Tuesday, a major step towards finalizing a proposed opioid ...

Too often, the disconnect between a company’s IT department and its business teams slows progress and leads to missed ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Mira Pharmaceuticals is making moves in weight loss and smoking cessation. The biotech is trying to buy Skny Pharmaceuticals ...